Journal Article

Efficacy of a mouthwash containing ε-poly-L-lysine, funme peptides and domiphen in reducing halitosis and supragingival plaque: a randomized clinical trial

Liu, Bin, Feng, Qiang, Liu, Xu, Meng, Lei, Shen, Song, Song, Wenzhu, Huang, Jun, Sun, Yi, Du, Mi

2024

Overview

Objective To evaluate the antibacterial effectiveness of a combination of ε-poly-L-lysine (ε-PL), funme peptide (FP) as well as domiphen against oral pathogens, and assess the efficacy of a BOP® mouthwash supplemented with this combination in reducing halitosis and supragingival plaque in a clinical trial. Materials and methods The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the compound against Fusobacterium nucleatum , Porphyromonas gingivalis , Streptococcus mutans , and Aggregatibacter actinomycetemcomitans were determined by the gradient dilution method. Subsequently, the CCK-8 assay was used to detect the toxicity of mouthwash on human gingival fibroblastst, and the effectiveness in reducing halitosis and supragingival plaque of the mouthwash supplemented with the combination was analyzed by a randomized, double-blind, parallel-controlled clinical trial. Results The combination exhibited significant inhibitory effects on tested oral pathogens with the MIC < 1.56% (v/v) and the MBC < 3.13% (v/v), and the mouthwash containing this combination did not inhibit the viability of human gingival fibroblasts at the test concentrations. The clinical trial showed that the test group displayed notably lower volatile sulfur compounds (VSCs) at 0, 10, 24 h, and 7 d post-mouthwash ( P  < 0.05), compared with the baseline. After 7 days, the VSC levels of the and control groups were reduced by 50.27% and 32.12%, respectively, and notably cutting severe halitosis by 57.03% in the test group. Additionally, the Plaque Index (PLI) of the test and control group decreased by 54.55% and 8.38%, respectively, and there was a significant difference in PLI between the two groups after 7 days ( P  < 0.01). Conclusions The combination of ε-PL, FP and domiphen demonstrated potent inhibitory and bactericidal effects against the tested oral pathogens, and the newly formulated mouthwash added with the combination exhibited anti-dental plaque and anti-halitosis properties in a clinical trial and was safe. Trial registration The randomized controlled clinical trial was registered on Chinese Clinical Trial Registry (No. ChiCTR2300073816, Date: 21/07/2023).

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Adult / Aggregatibacter actinomycetemcomitans - drug effects / Anti-Bacterial Agents - pharmacology / Anti-Bacterial Agents - therapeutic use / Antimicrobial agents / Antimicrobial peptides / Biofilms / Chloride / Cholecystokinin / Clinical trials / Dental plaque / Dental Plaque - microbiology / Dental Plaque - prevention & control / Dentistry / Double-Blind Method / Female / Fibroblasts - drug effects / Fusobacterium nucleatum - drug effects / Halitosis / Halitosis - drug therapy / Halitosis - microbiology / Halitosis - prevention & control / Humans / Ingredients / Male / Medicine / Microbial Sensitivity Tests / Microbiota / Microorganisms / Minimum bactericidal concentration / Minimum inhibitory concentration / Mouthwash / Mouthwashes / Mouthwashes - therapeutic use / Off odor / Oral and Maxillofacial Surgery / Oral hygiene / Pathogens / Peptides / Peptides - pharmacology / Peptides - therapeutic use / Plaque index / Poly-L-lysine / Polylysine - therapeutic use / Porphyromonas gingivalis - drug effects / Streptococcus mutans - drug effects / Sulfur compounds / Supragingival plaque / Systemic diseases / Toxicity / Young Adult